| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-01-05 |
Antabio (Fance) |
chief financial officer - clinical director - chief development officer
|
|
nomination |
Infectious diseases |
Nomination |
| 2018-01-05 |
Datavant (USA - CA) Duke Clinical Research Institute (DCRI) (USA - NC) |
healthcare data |
|
|
Technology - Services |
Collaboration agreement |
| 2018-01-05 |
Retrotope (USA - CA) Censa Pharmaceuticals (USA - MA) |
CNSA-001 |
phenylketonuria |
development |
Rare diseases - Genetic diseases - Metabolic diseases |
Development agreement |
| 2018-01-04 |
Pierre Fabre (France) Boston Pharmaceuticals (USA - MA) |
F17727 |
atrial fibrillation |
licensing |
Cardiovascular diseases |
Licensing agreement |
| 2018-01-04 |
Adaptimmune (UK) |
vice-president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-01-04 |
Arcturus Therapeutics (USA - CA) Curevac (Germany) |
up to four messenger RNA (mRNA) therapeutics for enzyme replacement and antibody generation |
ornithine transcarbamylase deficiency |
development |
Rare diseases - Genetic diseases |
Development agreement |
| 2018-01-03 |
Allergan (USA) Molecular Partners (Switzerland) |
therapeutic DARPin® products including dual anti-VEGF-A/PDGF-B DARPin® MP0260, abicipar and its corresponding backups |
exudative age-related macular degeneration (AMD) and related conditions, serious ophthalmic diseases |
research - development - licensing - commercialisation |
Ophtalmological diseases |
Exercise of an option agreement |
| 2018-01-03 |
Myriad Genetics (USA - UT) AstraZeneca (UK) |
companion diagnostics for the olaparib Phase 3 clinical development program,, myChoice® HRD Plus |
various tumor types including BRCA-mutated breast and ovarian cancers |
collaboration - development |
Cancer - Oncology |
Collaboration agreement |
| 2018-01-03 |
Janssen Biotech, a J&J company (USA - NJ) Alligator Bioscience (Sweden) |
ADC-1013 (JNJ64457107) |
|
licensing |
Cancer - Oncology |
Milestone |
| 2018-01-03 |
Nicox (France) |
|
|
nomination |
Ophtalmological diseases |
Nomination |
| 2018-01-03 |
Oxford BioDynamics (UK) undisclosed major US biopharmaceutical company |
- EpiSwitch™ technology for use in the development of new predictive biomarkers for immuno-oncology therapies
- EpiSwitch™ technology for use in the analysis of structure-function of genome architecture and new insights into fibrotic mechanisms, new targets and new biomarkers
|
|
collaboration - development |
Cancer - Oncology - Fibrotic diseases |
Collaboration agreement |
| 2018-01-03 |
Anthera Pharmaceuticals (USA - CA) |
vice-president |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-01-03 |
Pfizer (USA - NY) Sangamo Therapeutics (USA - CA) |
gene therapy using zinc finger protein transcription factors (ZFP-TFs) |
gene therapy using zinc finger protein transcription factors (ZFP-TFs) |
development |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
Development agreement |
| 2018-01-03 |
Datavant (USA - CA) |
chief scientific officer (CSO) |
|
nomination |
Technology - Services |
Nomination |
| 2018-01-03 |
Syntimmune (USA - MA) |
president and chief executive officer |
|
nomination |
Autoimmune diseases |
Nomination |
| 2018-01-03 |
Boston Pharmaceuticals (USA - MA) |
chief medical officer |
|
nomination |
|
Nomination |
| 2018-01-02 |
PharmaMar (Spain) Megapharm (Israel) |
Aplidin® (plitidepsin) |
multiple myeloma |
licensing - commercialisation - distribution |
Cancer - Oncology |
Licensing agreement |
| 2018-01-02 |
LogicBio Therapeutics (USA - MA) |
- chief business officer - vice president - clinical and regulatory strategist
|
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-12-27 |
Shire (UK - USA) |
plasma manufacturing facility in Covington |
|
validation of a production plant |
Rare diseases - Genetic diseases - Hematological diseases |
Validation of a production plant |
| 2017-12-27 |
Kazia Therapeutics (Australia), previously known as Novogen - Noxopharm (Australia) |
NOX66 (idronoxil) |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
